Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 55.70

-4.1%

11:46 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Icebrg who wrote (8825)	7/14/2003 11:29:52 PM
From: Biomaven	of 52153

MDX-070 has nothing to do with MEDI. You are correct of course - my mix-up. MEDI's only announced prostate cancer trial is using Vitaxin. Details of the proposed effect on bone mets is on slide 93 of their analyst day presentation. I think MEDI also mentioned their EphA2 program in the context of prostate, but the IND for that is only scheduled for 1H04. Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next